Floatz logo

cc-5013

Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome

M.D. Anderson Cancer CenterPhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
81/ 100

Competitive context

79 Active assets in the Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome cohort.

Asset / SponsorPhaseRating
Daunorubicin
National Cancer Institute (NCI)
Phase 3BBB
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 3BBB
FILGRASTIM
City of Hope Medical Center
Phase 2/3BBB
ETOPOSIDE
M.D. Anderson Cancer Center
Phase 3BB
Idarubicine
Fred Hutchinson Cancer Center
Phase 2/3BB

View all 50 →

Same molecule, other indications

cc-5013 is also rated in:

B-cell non-Hodgkin lymphomaDormant
BBB
Indicative ·
75 / 100
View asset →
Recurrent Adult Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
adult T-cell leukemia/lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →